Does a Patient-Directed Financial Incentive Affect Patient Choices About Controller Medicines for Asthma? A Discrete Choice Experiment and Financial Impact Analysis | Zendy

TraceyLea Laba | Zendy; Helen K. Reddel | Zendy; Nicholas Zwar | Zendy; Guy B. Marks | Zendy; Elizabeth E. Roughead | Zendy; Anthony Flynn | Zendy; Michele Goldman | Zendy; Aine Heaney | Zendy; Kirsty Lembke | Zendy; Stephen Jan | Zendy

Open Access

Does a Patient-Directed Financial Incentive Affect Patient Choices About Controller Medicines for Asthma? A Discrete Choice Experiment and Financial Impact Analysis

Author(s) -

TraceyLea Laba,

Helen K. Reddel,

Nicholas Zwar,

Guy B. Marks,

Elizabeth E. Roughead,

Anthony Flynn,

Michele Goldman,

Aine Heaney,

Kirsty Lembke,

Stephen Jan

Publication year - 2018

Publication title -

pharmacoeconomics

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.809

H-Index - 100

eISSN - 1179-2027

pISSN - 1170-7690

DOI - 10.1007/s40273-018-0731-5

Subject(s) - asthma , medicine , payment , health economics , government (linguistics) , incentive , affect (linguistics) , business , actuarial science , finance , economics , public health , nursing , microeconomics , psychology , linguistics , philosophy , communication

In Australia, many patients who are initiated on asthma controller inhalers receive combination inhaled corticosteroid/long-acting beta 2 -agonist (ICS/LABA) despite having asthma of sufficiently low severity that ICS-alone would be equally effective and less costly for the government.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research